Similar articles

• Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan.

  Nakashima I, Nakahara J, Yokote H, Manabe Y, Okamura K, Hasegawa K, Fujihara K. Nakashima I, et al. Ther Adv Neurol Disord. 2023 Jun 30;16:17562864231181177. doi: 10.1177/17562864231181177. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37441104 Free PMC article.
• Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment.

  Sen S, Tuncer A, Terzi M, Bunul SD, Ozen-Acar P, Altunrende B, Ozakbas S, Tutuncu M, Uygunoglu U, Akman-Demir G, Karabudak R, Efendi H, Siva A. Sen S, et al. Mult Scler Relat Disord. 2023 Nov;79:104949. doi: 10.1016/j.msard.2023.104949. Epub 2023 Aug 25. Mult Scler Relat Disord. 2023. PMID: 37678131
• Targeting the complement system in neuromyelitis optica spectrum disorder.

  Asavapanumas N, Tradtrantip L, Verkman AS. Asavapanumas N, et al. Expert Opin Biol Ther. 2021 Aug;21(8):1073-1086. doi: 10.1080/14712598.2021.1884223. Epub 2021 Feb 16. Expert Opin Biol Ther. 2021. PMID: 33513036 Free PMC article. Review.
• Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.

  Doubrovinskaja S, Korporal-Kuhnke M, Jarius S, Haas J, Wildemann B. Doubrovinskaja S, et al. J Neurol. 2024 May;271(5):2866-2870. doi: 10.1007/s00415-023-12071-9. Epub 2023 Nov 14. J Neurol. 2024. PMID: 37962590 Free PMC article.
• Advances in the long-term treatment of neuromyelitis optica spectrum disorder.

  Anderson M, Levy M. Anderson M, et al. J Cent Nerv Syst Dis. 2024 Feb 1;16:11795735241231094. doi: 10.1177/11795735241231094. eCollection 2024. J Cent Nerv Syst Dis. 2024. PMID: 38312734 Free PMC article. Review.